The Life Sciences team advised Zafgen (“ZFGN”) on the closing of its follow-on public offering of 9,200,000 shares of its common stock at a price of $7.50 per share, including the exercise in full by the underwriters of their option to purchase up to 1,200,000 additional shares. The offering resulted in total gross proceeds of $69 million, before deducting the underwriting discounts and commissions and other estimated offering expenses.
Zafgen is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases.
The Goodwin team included partners Mitchell Bloom, Danielle Lauzon and Theresa Kavanaugh; and associate Shoaib Ghias.
For more information on the offering, please read the press release.